Skip to main content Help with accessibility Skip to main navigation

Guidelines

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies

 

Documents

Date Added: 28 - Sep - 2022

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ixekizumab in the management of ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407, NICE TA497, NICE TA718 and NICE TA719..

Prescribing pathway

Body System:
Date Added: 25 - Sep - 2019

Application form for providers to apply to commissioners for in-year funding .

Body System:
No RAG
Date Added: 26 - May - 2017
Body System:
Date Added: 28 - Apr - 2022

The Pan Mersey Area Prescribing Committee recommends the prescribing of biologic agents, by specialists only, for Juvenile Idiopathic Arthritis (JIA) as per NICE TA373, TA238, TA 685 and TA735 in adult and paediatric services

Body System:
Date Added: 27 - Apr - 2022

The Pan Mersey Area Prescribing Committee recommends the prescribing of biological agents (adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab and ustekinumab) by specialists only, for inflammatory monoarthritis or oligoarthritis as specified.

MONOARTHRITIS or OLIGOARTHRITIS pathway

Monoarthritis or oligoarthritis, inflammatory: biological agents (South Sefton and Southport and Formby CCGs)

Monoarthritis or oligoarthritis pathway (South Sefton and Southport & Formby CCGs)

Body System:
Date Added: 28 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends the sequential use of high cost agents, adalimumab, apremilast▼, certolizumab, etanercept, golimumab, infliximab, ixekizumab▼, secukinumab▼, tofacitinib▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying Cheshire and Merseyside harmonised high cost drugs pathway.

High Cost Drugs Pathway for Psoriatic Arthritis

 

Body System:
Date Added: 28 - Apr - 2022

Failure of intensive therapy with a combination of standard DMARDs (usually methotrexate, hydroxychloroquine and sulphasalazine)

Body System:
Date Added: 29 - Sep - 2022

The Pan Mersey Area Prescribing Committee recommends the prescribing of anakinra, etanercept, infliximab or tocilizumab in Adult Onset Still’s Disease.

STILL'S DISEASE, adult onset (AOSD): pathway for the management of

Body System: